Developing more targeted and safer immune response therapies.

• Organ transplant
  
  
• Immune modulation
  
  
• Oncology

• Anti-rejection therapy
  
  
• Induction therapy
  
  
• Immune modulation
  
  
• Oncology

• Tolera Therapeutics Announces closing of Series B-3 funding

• Tolera Therapeutics Announces Appointment of Linda C. Hogan, VP of Business Development
• Tolera Therapeutics granted Orphan Drug Designation for treatment of Type 1 diabetes mellitus
• Tolera granted Orphan Drug Designation for organ transplant rejection drug
  
• See Related Articles...